We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why Medtronic (MDT) Gained But Lagged the Market Today
Read MoreHide Full Article
The latest trading session saw Medtronic (MDT - Free Report) ending at $80.95, denoting a +0.91% adjustment from its last day's close. The stock's change was less than the S&P 500's daily gain of 1.26%. Meanwhile, the Dow experienced a rise of 0.8%, and the technology-dominated Nasdaq saw an increase of 1.77%.
Coming into today, shares of the medical device company had lost 4.66% in the past month. In that same time, the Medical sector lost 6.56%, while the S&P 500 lost 2.82%.
The investment community will be paying close attention to the earnings performance of Medtronic in its upcoming release. It is anticipated that the company will report an EPS of $1.36, marking a 4.62% rise compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $8.33 billion, up 2.95% from the year-ago period.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $5.45 per share and a revenue of $33.56 billion, representing changes of +4.81% and +3.69%, respectively, from the prior year.
Investors should also pay attention to any latest changes in analyst estimates for Medtronic. These recent revisions tend to reflect the evolving nature of short-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the company's business operations and its ability to generate profits.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Currently, Medtronic is carrying a Zacks Rank of #3 (Hold).
Looking at its valuation, Medtronic is holding a Forward P/E ratio of 14.71. This signifies a discount in comparison to the average Forward P/E of 18.68 for its industry.
It's also important to note that MDT currently trades at a PEG ratio of 2.27. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. By the end of yesterday's trading, the Medical - Products industry had an average PEG ratio of 2.19.
The Medical - Products industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 87, positioning it in the top 35% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Here's Why Medtronic (MDT) Gained But Lagged the Market Today
The latest trading session saw Medtronic (MDT - Free Report) ending at $80.95, denoting a +0.91% adjustment from its last day's close. The stock's change was less than the S&P 500's daily gain of 1.26%. Meanwhile, the Dow experienced a rise of 0.8%, and the technology-dominated Nasdaq saw an increase of 1.77%.
Coming into today, shares of the medical device company had lost 4.66% in the past month. In that same time, the Medical sector lost 6.56%, while the S&P 500 lost 2.82%.
The investment community will be paying close attention to the earnings performance of Medtronic in its upcoming release. It is anticipated that the company will report an EPS of $1.36, marking a 4.62% rise compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $8.33 billion, up 2.95% from the year-ago period.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $5.45 per share and a revenue of $33.56 billion, representing changes of +4.81% and +3.69%, respectively, from the prior year.
Investors should also pay attention to any latest changes in analyst estimates for Medtronic. These recent revisions tend to reflect the evolving nature of short-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the company's business operations and its ability to generate profits.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Currently, Medtronic is carrying a Zacks Rank of #3 (Hold).
Looking at its valuation, Medtronic is holding a Forward P/E ratio of 14.71. This signifies a discount in comparison to the average Forward P/E of 18.68 for its industry.
It's also important to note that MDT currently trades at a PEG ratio of 2.27. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. By the end of yesterday's trading, the Medical - Products industry had an average PEG ratio of 2.19.
The Medical - Products industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 87, positioning it in the top 35% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.